NCT03471078 2023-09-28
Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers
Sobi, Inc.
Phase 3 Completed
Clinical Trials
12 trialsNCT01957176 2022-12-30
A Rollover Study to Provide Continued Treatment With Eltrombopag
Novartis
Phase 4 Completed
NCT02055781 2021-11-18
PAC326
CTI BioPharma
Phase 3 Terminated
NCT02964325 2021-08-19
MIPLATE
Terumo BCTbio
Phase NA Terminated
NCT01773187 2020-09-29
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
CTI BioPharma
Phase 3 Terminated
NCT01890746 2019-09-11
A Safety and Efficacy Study of Eltrombopag in Subjects With AML
Novartis
Phase 2 Completed
NCT02389621 2018-10-30
L-PLUS 2
Shionogi Inc.
Phase 3 Completed
NCT01440374 2017-06-05
ASPIRE
Novartis
Phase 2 Completed
NCT01444417 2017-02-09
Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
Amgen
Phase 3 Completed
NCT01147809 2016-04-18
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
GlaxoSmithKline
Phase 2 Completed
NCT00413283 2013-10-24
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
Amgen
Phase 2 Completed
NCT00283439 2011-06-20
A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma
Amgen
Phase 1/2 Completed